Ponatinib (Iclusig) is a new-generation kinase inhibitor that exhibits unique efficacy in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myeloid leukemia (CML).

What Are the Purchase Channels for Ponatinib (Iclusig)?

Overseas Purchase

Patients may choose to consult and purchase ponatinib at hospital pharmacies or authorized pharmacies in countries or regions where the drug has been launched.

Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make a budget and plan in advance before purchasing.

Purchase Through Medical Service Institutions

Patients can consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

These institutions can usually provide legal import channels and offer professional consultation and guidance.

Precautions for Purchasing Ponatinib (Iclusig)

Prescription Compliance Requirements

As a strictly regulated prescription drug, ponatinib must be purchased with a valid prescription issued by a physician.

Any over-the-counter sales of the drug are illegal and may pose significant medication risks.

Standardized Dosage Management

Newly diagnosed Ph+ ALL (in combination with chemotherapy): The initial dose is 30 mg taken orally once daily. After achieving minimal residual disease (MRD)-negative complete remission (CR) at the end of induction therapy, the dose is reduced to 15 mg taken orally once daily.

Ph+ ALL (monotherapy): The initial dose is 45 mg taken orally once daily.

Chronic phase CML (CP-CML) treatment: The initial dose is 45 mg taken orally once daily. After achieving a BCR::ABL1 international scale (IS) value of ≤1%, the dose is reduced to 15 mg taken orally once daily.

Accelerated phase CML (AP-CML) and blast phase CML (BP-CML) treatment: The initial dose is 45 mg taken orally once daily.

Contraindications for Special Populations

Pregnant women: The use of ponatinib is explicitly contraindicated, as it may cause harm to the fetus.

Lactating women: Breastfeeding is not recommended during treatment and for 1 week after the last dose.

Patients with hepatic impairment: Dosage adjustments are required based on specific conditions.

Authentication of Ponatinib (Iclusig) Authenticity

Verification of Packaging Information

Approval number verification: The official approval number issued by the FDA (U.S. Food and Drug Administration) must be checked.

Confirmation of the manufacturer: The drug is produced and marketed by Takeda Pharmaceuticals America, Inc.

Anti-counterfeiting label: The label shall clearly state "Store in the original container to protect from moisture".

Comparison of Drug Appearance Characteristics

10 mg tablet characteristics: Oval, white to off-white, biconvex film-coated tablet, engraved with "NZ" on one side and blank on the other side.

15 mg tablet characteristics: Round, white, biconvex film-coated tablet, engraved with "A5" on one side and blank on the other side.

30 mg tablet characteristics: Round, white, biconvex film-coated tablet, engraved with "C7" on one side and blank on the other side.

45 mg tablet characteristics: Round, white, biconvex film-coated tablet, engraved with "AP4" on one side and blank on the other side.